Eledon Pharmaceuticals (ELDN) Competitors

Eledon Pharmaceuticals logo
$1.98 +0.01 (+0.51%)
Closing price 04:00 PM Eastern
Extended Trading
$2.00 +0.02 (+1.26%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ELDN vs. GLUE, IMTX, SNDX, ALMS, and LXRX

Should you buy Eledon Pharmaceuticals stock or one of its competitors? Eledon Pharmaceuticals's main competitors and comparable companies include Monte Rosa Therapeutics (GLUE), Immatics (IMTX), Syndax Pharmaceuticals (SNDX), Alumis (ALMS), and Lexicon Pharmaceuticals (LXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eledon Pharmaceuticals compare to Monte Rosa Therapeutics?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Monte Rosa Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A
Monte Rosa Therapeutics$123.67M6.27-$38.63M-$1.40N/A

Eledon Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 405.05%. Monte Rosa Therapeutics has a consensus price target of $26.44, indicating a potential upside of 191.56%. Given Eledon Pharmaceuticals' higher possible upside, equities analysts plainly believe Eledon Pharmaceuticals is more favorable than Monte Rosa Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Monte Rosa Therapeutics
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75

Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -186.24%. Monte Rosa Therapeutics' return on equity of -30.14% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -160.61% -55.54%
Monte Rosa Therapeutics -186.24%-30.14%-20.35%

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 7 mentions for Monte Rosa Therapeutics and 6 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.55 beat Monte Rosa Therapeutics' score of -0.07 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Monte Rosa Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Monte Rosa Therapeutics beats Eledon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Immatics?

Immatics (NASDAQ:IMTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Eledon Pharmaceuticals had 5 more articles in the media than Immatics. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 1 mentions for Immatics. Eledon Pharmaceuticals' average media sentiment score of 0.55 beat Immatics' score of -0.49 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immatics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Eledon Pharmaceuticals has lower revenue, but higher earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immatics$54.60M15.75-$222.26M-$1.95N/A
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -533.26%. Immatics' return on equity of -52.54% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Immatics-533.26% -52.54% -43.30%
Eledon Pharmaceuticals N/A -160.61%-55.54%

Immatics has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

64.4% of Immatics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Immatics currently has a consensus target price of $19.00, indicating a potential upside of 202.07%. Eledon Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 405.05%. Given Eledon Pharmaceuticals' higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Summary

Eledon Pharmaceuticals beats Immatics on 8 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Syndax Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 3 mentions for Syndax Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.55 beat Syndax Pharmaceuticals' score of 0.17 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Syndax Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Eledon Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 405.05%. Syndax Pharmaceuticals has a consensus price target of $41.60, suggesting a potential upside of 352.17%. Given Eledon Pharmaceuticals' higher possible upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Syndax Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Syndax Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Eledon Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Syndax Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Syndax Pharmaceuticals' net margin of -72.32%. Eledon Pharmaceuticals' return on equity of -160.61% beat Syndax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -160.61% -55.54%
Syndax Pharmaceuticals -72.32%-804.38%-34.93%

Eledon Pharmaceuticals has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A
Syndax Pharmaceuticals$172.35M4.81-$285.42M-$2.36N/A

Summary

Eledon Pharmaceuticals beats Syndax Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Alumis?

Alumis (NASDAQ:ALMS) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

Eledon Pharmaceuticals has lower revenue, but higher earnings than Alumis. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alumis$24.05M26.05-$243.32M-$3.53N/A
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A

Eledon Pharmaceuticals has a net margin of 0.00% compared to Alumis' net margin of -5,844.54%. Alumis' return on equity of -89.77% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alumis-5,844.54% -89.77% -71.50%
Eledon Pharmaceuticals N/A -160.61%-55.54%

Alumis currently has a consensus target price of $31.27, suggesting a potential upside of 546.13%. Eledon Pharmaceuticals has a consensus target price of $10.00, suggesting a potential upside of 405.05%. Given Alumis' stronger consensus rating and higher possible upside, research analysts clearly believe Alumis is more favorable than Eledon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alumis
1 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.86
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Alumis has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, Alumis had 24 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 30 mentions for Alumis and 6 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.55 beat Alumis' score of -0.07 indicating that Eledon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alumis
2 Very Positive mention(s)
5 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Alumis beats Eledon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Eledon Pharmaceuticals compare to Lexicon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Eledon Pharmaceuticals has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eledon PharmaceuticalsN/AN/A-$45.62M-$0.73N/A
Lexicon Pharmaceuticals$49.80M15.91-$50.34M-$0.14N/A

In the previous week, Eledon Pharmaceuticals had 3 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Eledon Pharmaceuticals and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.96 beat Eledon Pharmaceuticals' score of 0.55 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eledon Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Lexicon Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Eledon Pharmaceuticals has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Eledon Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 405.05%. Lexicon Pharmaceuticals has a consensus price target of $5.80, suggesting a potential upside of 225.84%. Given Eledon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Eledon Pharmaceuticals is more favorable than Lexicon Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eledon Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Lexicon Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Eledon Pharmaceuticals has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -161.80%. Lexicon Pharmaceuticals' return on equity of -35.76% beat Eledon Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Eledon PharmaceuticalsN/A -160.61% -55.54%
Lexicon Pharmaceuticals -161.80%-35.76%-24.53%

56.8% of Eledon Pharmaceuticals shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Lexicon Pharmaceuticals beats Eledon Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

Get Eledon Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ELDN vs. The Competition

MetricEledon PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$166.39M$4.06B$7.82B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E Ratio-2.7125.6832.7626.82
Price / SalesN/A16.068.565.70
Price / CashN/A22.9521.0121.90
Price / Book5.504.184.463.72
Net Income-$45.62M-$24.15M$3.52B$393.10M
7 Day Performance-28.26%-7.25%-5.47%-4.73%
1 Month Performance-7.04%-5.98%-4.57%-7.14%
1 Year Performance22.22%-7.72%-1.79%-7.51%

Eledon Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ELDN
Eledon Pharmaceuticals
1.8472 of 5 stars
$1.98
+0.5%
$10.00
+405.1%
+11.9%$166.39MN/AN/A33
GLUE
Monte Rosa Therapeutics
1.9489 of 5 stars
$10.50
-0.8%
$26.44
+151.9%
-36.2%$895.76M$123.67MN/A173
IMTX
Immatics
3.2251 of 5 stars
$6.42
-0.2%
$19.00
+196.0%
-39.5%$877.55M$54.60MN/A704
SNDX
Syndax Pharmaceuticals
2.4255 of 5 stars
$9.49
-0.6%
$41.60
+338.4%
-45.1%$854.39M$172.35MN/A298
ALMS
Alumis
3.663 of 5 stars
$6.40
-2.3%
$33.27
+419.9%
-6.9%$828.35M$24.05MN/A239

Related Companies and Tools


This page (NASDAQ:ELDN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners